Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Korean J Gastroenterol ; 47(1): 15-21, 2006 Jan.
Article in Korean | MEDLINE | ID: mdl-16434864

ABSTRACT

BACKGROUND/AIMS: This study was done to evaluate the efficacy of rabeprazole (proton-pump-inhibitor) and ranitidine (H(2)-receptor antagonist) in the symptom relief and treatment of erosive esophagitis diagnosed by endoscopy. METHODS: A total of 110 patients with typical gastroesophageal reflux disease (GERD) symptoms were enrolled in this multicenter study. They were randomized into rabeprazole group (53 patients) and ranitidine group (57 patients) respectively. The patients in rabeprazole group were given 10 mg of rabeprazole and ranitidine group received 300 mg of ranitidine before breakfast and dinner for 8 weeks. After the end of treatment, we evaluated the endoscopic healing rate of reflux esophagitis and symptomatic improvement. RESULTS: After 8 weeks of treatment, rabeprazole group showed significantly higher complete endoscopic cure rate than ranitidine group (86.8% [46/53] vs. 57.9% [33/57], p=0.001) and higher symptomatic improvement of heartburn (91.2% [31/34] vs. 76.2% [32/42], p=0.085), especially in the first 7 days (76.7% vs. 45.3%, p=0.008). Also, rabeprazole group showed significantly higher improvement of regurgitation symptom than ranitidine group (100% [35/35] vs. 83% [39/47], p=0.009). Both group showed no differences in the improvement of chest pain and globus sensation. All the adverse events (rabeprazole group 4 events vs. ranitidine group 3 events) were mild and there was no abnormality in laboratory test. CONCLUSIONS: In patients with GERD, rabeprazole 10 mg b.i.d. is superior to ranitidine 300 mg b.i.d. in healing of reflux esophagitis and resolving typical GERD symptoms. Rabeprazole is an effective and well-tolerated drug for GERD treatment.


Subject(s)
Anti-Ulcer Agents/therapeutic use , Benzimidazoles/therapeutic use , Esophagitis, Peptic/drug therapy , Histamine H2 Antagonists/therapeutic use , Omeprazole/analogs & derivatives , Proton Pump Inhibitors , Ranitidine/therapeutic use , 2-Pyridinylmethylsulfinylbenzimidazoles , Adult , Female , Humans , Male , Middle Aged , Omeprazole/therapeutic use , Proton-Translocating ATPases/therapeutic use , Rabeprazole
2.
Article in Korean | WPRIM (Western Pacific) | ID: wpr-157134

ABSTRACT

BACKGROUND/AIMS: This study was done to evaluate the efficacy of rabeprazole (proton-pump-inhibitor) and ranitidine (H2-receptor antagonist) in the symptom relief and treatment of erosive esophagitis diagnosed by endoscopy. METHODS: A total of 110 patients with typical gastroesophageal reflux disease (GERD) symptoms were enrolled in this multicenter study. They were randomized into rabeprazole group (53 patients) and ranitidine group (57 patients) respectively. The patients in rabeprazole group were given 10 mg of rabeprazole and ranitidine group received 300 mg of ranitidine before breakfast and dinner for 8 weeks. After the end of treatment, we evaluated the endoscopic healing rate of reflux esophagitis and symptomatic improvement. RESULTS: After 8 weeks of treatment, rabeprazole group showed significantly higher complete endoscopic cure rate than ranitidine group (86.8% [46/53] vs. 57.9% [33/57], p=0.001) and higher symptomatic improvement of heartburn (91.2% [31/34] vs. 76.2% [32/42], p=0.085), especially in the first 7 days (76.7% vs. 45.3%, p=0.008). Also, rabeprazole group showed significantly higher improvement of regurgitation symptom than ranitidine group (100% [35/35] vs. 83% [39/47], p=0.009). Both group showed no differences in the improvement of chest pain and globus sensation. All the adverse events (rabeprazole group 4 events vs. ranitidine group 3 events) were mild and there was no abnormality in laboratory test. CONCLUSIONS: In patients with GERD, rabeprazole 10 mg b.i.d. is superior to ranitidine 300 mg b.i.d. in healing of reflux esophagitis and resolving typical GERD symptoms. Rabeprazole is an effective and well-tolerated drug for GERD treatment.


Subject(s)
Adult , Female , Humans , Male , Middle Aged , 2-Pyridinylmethylsulfinylbenzimidazoles , Anti-Ulcer Agents/therapeutic use , Benzimidazoles/therapeutic use , Esophagitis, Peptic/drug therapy , Histamine H2 Antagonists/therapeutic use , Omeprazole/analogs & derivatives , Proton Pumps/antagonists & inhibitors , Proton-Translocating ATPases/therapeutic use , Ranitidine/therapeutic use
3.
Dig Dis Sci ; 48(4): 657-62, 2003 Apr.
Article in English | MEDLINE | ID: mdl-12741452

ABSTRACT

Gastroesophageal reflux disease (GERD) is characterized by heartburn and related symptoms that are distressing to patients and interfere with everyday functioning and well-being. A measure of symptom distress, the GERD Symptom Assessment Scale (GSAS), was included in two randomized, placebo-controlled trials of rabeprazole among patients with nonerosive GERD. The age (mean +/- SD) of the 223 patients was 43.5 +/- 11.9 years, and most were female (67%) and Caucasian (78%). Significantly greater reductions in symptom distress were observed among patients receiving rabeprazole 20 mg daily for 4 weeks relative to those receiving placebo (-0.62 vs -0.36, P < 0.0001). The magnitude of this treatment difference was comparable to the differences observed between levels of overall symptom improvement on the patient global rating (0.2 and 0.3 points; P < 0.0001). In conclusion, reducing symptom distress is an important goal of therapeutic interventions for GERD. Rabeprazole significantly reduced the distress associated with a broad range of GERD symptoms, and the magnitude of this effect was meaningful to patients.


Subject(s)
Benzimidazoles/therapeutic use , Esophagitis, Peptic/drug therapy , Gastroesophageal Reflux/drug therapy , Outcome Assessment, Health Care/statistics & numerical data , Patient Satisfaction , Proton-Translocating ATPases/therapeutic use , 2-Pyridinylmethylsulfinylbenzimidazoles , Adult , Benzimidazoles/adverse effects , Double-Blind Method , Esophagitis, Peptic/diagnosis , Esophagitis, Peptic/psychology , Female , Gastroesophageal Reflux/diagnosis , Gastroesophageal Reflux/psychology , Humans , Male , Middle Aged , Omeprazole/analogs & derivatives , Proton-Translocating ATPases/adverse effects , Proton-Translocating ATPases/antagonists & inhibitors , Psychometrics , Rabeprazole , Randomized Controlled Trials as Topic , Sick Role
4.
Digestion ; 66(3): 154-9, 2002.
Article in English | MEDLINE | ID: mdl-12481161

ABSTRACT

BACKGROUND: Rabeprazole has been demonstrated to be a potent antisecretory agent and has been shown to be clinically effective in the treatment of acid-related diseases. AIMS: It was to determine the efficacy of rabeprazole at 20 and 40 mg in addition to amoxicillin and clarithromycin in the treatment of active Helicobacter pylori-positive duodenal ulcers compared with omeprazole 40 mg. PATIENTS AND METHODS: One hundred and twenty-seven patients were randomised into three treatment groups: 40 patients were treated with rabeprazole 40 mg daily, 42 patients with rabeprazole 20 mg daily and 45 patients with omeprazole 40 mg daily for 10 days. All patients received amoxicillin 1 g twice a day and clarithromycin 500 mg twice a day for 5 days. All patients were re-assessed at least 4 weeks after the end of the treatment. RESULTS: According to the intention-to-treat (ITT) protocol, ulcer healing was observed in 90% of patients in the rabeprazole 40 group, in 85.7% in the rabeprazole 20 group and in 93.3% in the omeprazole 40 group. We observed H. pylori eradication in 90% ITT in the rabeprazole 40 group, in 80.9% ITT in the rabeprazole 20 group and in 88.8% ITT in the omeprazole 40 group. Statistical analysis did not show significant differences among the three groups. CONCLUSIONS: A 10-day rabeprazole 20 mg regimen represents an efficacious and safe regimen for H. pylori eradication and ulcer healing.


Subject(s)
Anti-Ulcer Agents/therapeutic use , Benzimidazoles/therapeutic use , Duodenal Ulcer/drug therapy , Omeprazole/therapeutic use , 2-Pyridinylmethylsulfinylbenzimidazoles , Adult , Amoxicillin/therapeutic use , Clarithromycin/therapeutic use , Drug Administration Schedule , Drug Therapy, Combination , Female , Helicobacter Infections/drug therapy , Helicobacter pylori , Humans , Male , Patient Compliance , Prospective Studies , Proton-Translocating ATPases/therapeutic use , Rabeprazole
5.
Dig Liver Dis ; 33(8): 671-5, 2001 Nov.
Article in English | MEDLINE | ID: mdl-11785712

ABSTRACT

BACKGROUND: Omeprazole is mainly metabolized by cytochrome P450 2C19 (CYP2C19) in the liver. Rabeprazole, on the other hand, is mainly metabolized to thioether-rabeprazole via a non-enzymatic pathway and partially metabolized to demethylated-rabeprazole by CYP2C19 in liver CYP2C19 status may affect cure rate for Helicobacter pylori infection with proton pump inhibitor triple therapy. AIM: To investigate whether genetic polymorphism of CYP2C19 and selected proton pump inhibitors (omeprazole or rabeprazole) were associated with cure rate for Helicobacter pylori infection using triple therapy with omeprazole or rabeprazole, amoxicillin, and clarithromycin. METHODS: A total of 170 Helicobacter pylori-positive patients with chronic gastritis were randomized to receive one of the following Helicobacter pylori eradication regimens; OAC (omeprazole 20 mg bd, amoxycillin 750 mg bd and clarithromycin 400 mg bd for 1 week) and RAC (rabeprazole 20 mg bd, amoxycillin 750 mg bd and clarithromycin 400 mg bd for 1 week). The CYP2C19 genotype; wild-type or two mutant genes (ml in exon 5 and m2 in exon 4), or both, were identified by polymerase chain reaction-restriction fragment length polymorphism. RESULTS: In DAC regimen, cure rate (per protocol analysis) was 73.3% in homozygous extensive metabolizers, 86.1% in heterozygous extensive metabolizers, and 85.0% in poor metabolizers. In RAC regimen, the cure rate was 81.0% in homozygous extensive metabolizers, 82.9% in heterozygous extensive metabolizers, and 87.5% in poor metabolizers. Cure rate was not significantly different between the CYP2C19 genotypes in both regimens. CONCLUSION: Triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxycillin, and clarithromycin is sufficiently effective in cure of Helicobacter pylori infection regardless of CYP2C19 status.


Subject(s)
Aryl Hydrocarbon Hydroxylases , Benzimidazoles/therapeutic use , Cytochrome P-450 Enzyme System/genetics , Helicobacter Infections/drug therapy , Helicobacter pylori , Mixed Function Oxygenases/genetics , Omeprazole/therapeutic use , Polymorphism, Genetic , Proton-Translocating ATPases/therapeutic use , 2-Pyridinylmethylsulfinylbenzimidazoles , Adult , Amoxicillin/therapeutic use , Clarithromycin/therapeutic use , Cytochrome P-450 CYP2C19 , Drug Therapy, Combination , Female , Gastritis/drug therapy , Gastritis/microbiology , Genotype , Helicobacter Infections/genetics , Humans , Japan , Male , Middle Aged , Prospective Studies , Rabeprazole , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...